3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
30
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
8
Stomach Neoplasms
7
Neoplasms
6
Colorectal Neoplasms
6
Adenocarcinoma
6
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Advanced Solid Tumor
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Solid Cancer
1
Interventions
Temozolomide
32
Radiotherapy
11
Bevacizumab
10
Surgical Procedures, Operative
7
IL13-PE38
7
TIC10 compound
6
Lomustine
6
Carboplatin
6
Radiation
5
Chlorotoxin
5
vorasidenib
4
trametinib
4
dabrafenib
4
Valacyclovir
4
OKN 007
4
Flucytosine
4
Dianhydrogalactitol
4
Cyclophosphamide
4
vocimagene amiretrorepvec
3
abemaciclib
3
Paclitaxel
3
Nivolumab
3
Irinotecan
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
CLR1404
3
trans-sodium crocetinate
2
pembrolizumab
2
olutasidenib
2
marizomib
2
lenvatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Glioma
×
trastuzumab deruxtecan
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled